传统与生物改善病情抗风湿药对高安动脉炎动脉病变的影响
本研究用CT血管造影比较75个治疗线中传统改善病情抗风湿药(cDMARDs,40线)与生物改善病情抗风湿药(bDMARDs,35线)对高安动脉炎血管病变演变的影响。结果显示73%病例动脉壁厚度整体减少,31%壁厚度相对减少超过25%;bDMARDs相较cDMARDs与血管壁厚度减少独立相关(P=0.026),且管腔直径相对增加超过25%在bDMARDs组为56%、cDMARDs组为17%。作者认为免疫抑制治疗可减少动脉壁厚度并增宽管腔,bDMARDs似乎比cDMARDs更有效。
要点
- 73%的高安动脉炎病例在免疫抑制治疗下出现动脉壁厚度整体减少。
- bDMARDs相较cDMARDs与血管壁厚度减少独立相关(P=0.026)。
- 管腔直径相对增加超过25%在bDMARDs组为56%,cDMARDs组为17%。
核心结论
- 免疫抑制治疗可减少高安动脉炎患者的动脉壁厚度并增宽管腔直径。
- bDMARDs似乎比cDMARDs更有效地改善高安动脉炎的动脉病变。
研究设计与样本
- 研究比较了75个治疗线的高安动脉炎患者,其中cDMARDs组40线、bDMARDs组35线,均使用CT血管造影随访。
- 研究设定1至3条主要靶血管(存在血管壁增厚和/或狭窄),在免疫抑制治疗开始时及12个月时测量每条靶血管的壁厚度和管腔直径。
主要发现
- 73%的病例观察到动脉壁厚度整体减少,31%的病例壁厚度相对减少超过25%。
- 线性混合效应模型显示,一线免疫抑制治疗(P=0.012)和bDMARDs相较cDMARDs(P=0.026)与高安动脉炎血管壁厚度减少独立相关。
- 38%的狭窄血管在免疫抑制治疗下管腔直径相对增加超过25%。
- 管腔直径相对增加超过25%在bDMARDs组为56%,cDMARDs组为17%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The definition of Takayasu arteritis (TAK) remission and disease activity is still unclear. Vascular imaging is an essential tool for following-up patients. Herein, we aimed to compare the evolution of vascular lesions (i.e. vessel wall thickening and stenosis) under conventional cDMARDs relatively to biological DMARDs (bDMARDs) in TAK patients followed with the same CT angiography modalities. METHOD: We compared 75 lines of therapy in TAK patients who received cDMARDs (n = 40 lines) and bDMARDs (n = 35 lines) using CT angiography. We established 1-3 main target vessels with vessel wall thickening and/or stenosis. Every targeted vessel had its thickness and its lumen diameter measured at the initiation of immunosuppressive treatment and at 12 months. RESULTS: We observed an overall reduction in arterial wall thickness in 73% of cases and 31% had >25% relative decrease in the wall thickness. Using a linear mixed effects model, first-line immunosuppressive therapy (P = 0.012) and bDMARDs relatively to cDMARDs (P = 0.026) were independently associated with vessel wall thickness reduction in TAK. Thirty-eight percent of the stenotic vessels had a > 25% relative increase in lumen diameter under immunosuppressive therapy. The relative increase >25% in lumen diameter was noted in 56% vs 17% with bDMARDs compared with cDMARDs. CONCLUSION: Immunosuppressive treatments can reduce arterial wall thickness and widen lumen diameter in TAK. bDMARDs seem to be more effective than cDMARDs to improve arterial lesions in TAK.
引用
- Bletry D, Meyblum L, Desseaux K, et al. Impact of conventional and biological disease-modifying anti-rheumatic drugs on arterial lesions in Takayasu arteritis. Rheumatology (Oxford). 2025. PMID: 38970381. doi:10.1093/rheumatology/keae331
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。